Phastar to Provide Pro Bono Aid to Medicines Development for Global Health
Support to focus on two double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire.
Phastar, a biometrics contract research organization (CRO), announced that it will be providing pro bono support to Medicines Development for Global Health (MDGH), a nonprofit focused on the development of medicines for neglected diseases primarily affecting people living in low- and middle-income countries. As part of Phastar’s assistance, MDGH will have access to the company’s biometrics experts during two large double-blind Phase IIIb clinical studies in the Democratic Republic of Congo and Cote d’Ivoire. According to a company release, one trial will be focused on evaluating the safety of moxidectin and the second is evaluating repeat single dosing compared with ivermectin in individuals living in onchocerciasis (river blindness) endemic areas.
At Phastar, we have the expertise and the resources to make a meaningful difference and to deliver on our mission to improve human health. As a B Corp organization, we strive to be a force for good, and one of our strategic objectives is to lead the CRO industry in corporate social responsibility,” said Graham Clark, CEO, Phastar. “The Phastar Cares Scheme, which offers free access to our statisticians, data scientists, data managers, and programmers, is an important part of that commitment. We are proud to be in a position to help MDGH on their mission to eradicate onchocerciasis.”
Reference: Phastar Offers Pro Bono Support to Medicines Development for Global Health. Phastar. October 26, 2023. Accessed October 27, 2023. https://phastar.com/resources/news/318-phastar-offers-pro-bono-support-to-medicines-development-for-global-health
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
